



(43) International Publication Date
26 June 2014 (26.06.2014)

(10) International Publication Number
WO 2014/100818 A1

(51) International Patent Classification:
C07D 213/74 (2006.01)

(21) International Application Number:
PCT/US2013/077539

(22) International Filing Date:
23 December 2013 (23.12.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/745,246 21 December 2012 (21.12.2012) US
61/785,380 14 March 2013 (14.03.2013) US

(71) Applicant: **QUANTICEL PHARMACEUTICALS, INC.** [US/US]; 9393 Towne Centre Drive, Suite 110, San Diego, CA 92121 (US).

(72) Inventors: **CHEN, Young, K.**; 746 Santa Barbara Drive, San Marcos, CA 92078 (US). **KANOUNI, Toufike**; 9253 Regents Road, Unit A103, La Jolla, CA 92037 (US). **NIE, Zhe**; 17104 Monterey Ridge Way, San Diego, CA 92127 (US). **STAFFORD, Jeffrey, Alan**; 12752 Sandy Crest Court, San Diego, CA 92130 (US). **VEAL, James, Marvin**; 8916 Weaver Crossing Road, Apex, NC 92130 (US). **WALLACE, Michael, Brennan**; 3766 Tomahawk Lane, San Diego, CA 92117 (US).

(74) Agent: **HOSTETLER, Michael, J.**; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, CA 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: HISTONE DEMETHYLASE INHIBITORS

(57) Abstract: The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted amidopyridine or amidopyridazine derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.



WO 2014/100818 A1